title: [The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy].
abstract: Surgical resection of primary lesions and single metastasis can be curative, but surgery, used as the only therapeutic option, is not unanimously accepted in patients with multiple metastasis and, apart from other considerations, there are no established clinical criteria to allow us to predict which patients will benefit from a metastectomy. This study evaluates four patients with advanced RCC. Three had multiple pulmonary metastasis at the time of diagnosis and one presented retroperitoneal mass at 36 months of follow-up. All patients were nephrectomized and received adjuvant immunotherapy with an association of IL-2 and 2b alpha-IFN subcutaneously, obtaining partial response of the disease after two treatment courses. Later, the patients underwent debulking surgery. Two patients are still alive and have no evidence of disease progression at 28 months and 8 months of follow-up. This data and that contrasted with other authors, suggests that surgical management would be a reasonable option in patients who have partially responded to immunotherapy, even though the selection of both candidates and surgical strategy should be considered on an individual basis.
authors.affiliation: Servicio de Urología y Anatomía Patológica, Clínica Puerta de Hierro, Universidad de Alcalá de Henares, Madrid.
authors.forename: C
authors.initials: C
authors.lastname: Olivier
authors.forename: J
authors.initials: J
authors.lastname: Carballido
authors.forename: A H
authors.initials: AH
authors.lastname: Lao
authors.forename: D
authors.initials: D
authors.lastname: Bellido
authors.forename: S
authors.initials: S
authors.lastname: Ramón y Cajal
authors.forename: L
authors.initials: L
authors.lastname: Manzano
authors.forename: L
authors.initials: L
authors.lastname: Ondina
authors.forename: M
authors.initials: M
authors.lastname: Alvarez-Mon
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000601:surgery*; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000601:surgery*; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011994:Recombinant Proteins; D012186:Retroperitoneal Neoplasms / Q000556:secondary* / Q000628:therapy
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins
vernacular_title: Oportunidad de la cirugía en las lesiones metastáticas del carcinoma de células renales tras respuesta a la inmunoterapia adyuvante.